Understanding typical experiences helps patients navigate this initial phase with appropriate expectations and strategies
Another study found that semaglutide treatment significantly reduced liver fat levels in individuals living with non-alcoholic fatty liver disease, with over 70% of participants seeing benefit
Well review optionsincluding GLP-1s where appropriateand build a plan that blends medical care , therapy , and real-world relapse prevention .
On April 30, 2026, the U.S
Active Gastrointestinal Fluid Losses For a subset of patients, especially during initiation or dose-escalation phases, gastrointestinal side effects can be pronounced: Nausea: Constant, low-grade nausea frequently creates a psychological aversion to swallowing anything, including plain water